CD274 and neoplasm: In the luminal and TNBC subtypes, cDC-1 has been associated with improved disease-free survival (DFS) and positive patient outcomes through its activation and expansion of CD103, enhancing the tumor response to therapeutic programmed death-ligand 1 (PD-L1) and BRAF inhibition (141, 142).